Shares In IP Group, Diurnal Suffer After Chronocort Trial Disappoints
LONDON (Alliance News) - Diurnal Group PLC said Monday its phase-three European trial of Chronocort did not meet its primary objective, causing shares in the pharmaceutical company to property IP Read More